PM
MLYS icon

Prosight Management’s Mineralys Therapeutics MLYS Stock Holding History

Prosight Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Buy
+449,795
New +$12.3M 2.09% 16

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prosight Management's MLYS Position: Q2 2026 in Review

Prosight Management opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 449,795 shares worth $12.1M. The stake represents 2.09% of the portfolio and ranks #16 among its holdings.

224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Prosight Management held 449,795 shares of Mineralys Therapeutics worth $12.1M as of Q2 2026.
  • Mineralys Therapeutics was a new Prosight Management position in Q2 2026.
  • Mineralys Therapeutics made up 2.09% of Prosight Management's portfolio in Q2 2026, its #16 holding.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.